Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
-0.59 (-0.21%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 272.87 - 278.10
52 week 223.02 - 333.65
Open 277.08
Vol / Avg. 1.37M/1.71M
Mkt cap 58.82B
P/E 16.25
Div/yield     -
EPS 16.91
Shares 215.95M
Beta 0.80
Inst. own 89%
Jan 26, 2017
Q4 2016 Biogen Inc Earnings Release
Jan 26, 2017
Q4 2016 Biogen Inc Earnings Call
Jan 9, 2017
Biogen Inc at JPMorgan Healthcare Conference - Q&A
Jan 9, 2017
Biogen Inc at JPMorgan Healthcare Conference
Jan 6, 2017
Biogen Inc Bioverativ Investor Day
Jan 5, 2017
Biogen Inc at Goldman Sachs CEOs Unplugged Conference
Jan 5, 2017
Bioverativ at Goldman Sachs CEOs Unplugged Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 22.56% 32.28%
Operating margin 30.86% 44.99%
EBITD margin - 55.45%
Return on average assets 11.55% 17.44%
Return on average equity 21.47% 34.42%
Employees 7,400 -
CDP Score - 96 C


225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia


Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; BIIB061; BIIB054; BIIB067, and BIIB068.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Michel Vounatsos Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Michael D. Ehlers M.D., Ph.D. Executive Vice President, Head - Research and Development
Age: 48
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 54
Bio & Compensation  - Reuters
Paul McKenzie Ph.D. Executive Vice President - Pharmaceutical Operations & Technology
Age: 51
Bio & Compensation  - Reuters
Alfred W. Sandrock Jr., M.D., Ph.D. Executive Vice President - Neurology Discovery and Development and Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Gregory F. Covino Chief Accounting Officer, Vice President - Finance
Age: 51
Bio & Compensation  - Reuters